First-Of-Its-Kind AI-Enabled Smart Microscopy Platform to Improve Precision in Cancer Diagnostics
|
By LabMedica International staff writers Posted on 04 Aug 2023 |
|
Presently, drug developers and healthcare practitioners depend on antiquated methodologies to tackle increasingly complex tasks such as diagnosing diseases, quantifying biomarkers, and predicting responses to innovative treatments. Various companies have attempted to modernize the approach by digitizing specimens and adding more markers to a single slide, yet they still face the challenges of less than 1% of tissue specimens being analyzed and the inability to visualize complex structures and intercellular distributions in three dimensions. Now, a groundbreaking 3D spatial biology platform can rapidly digitize entire tissue specimens without causing any damage. The platform also provides AI-powered quantitative analysis to respond to crucial queries from clinicians and drug developers with greater precision and certainty.
Alpenglow Biosciences (Seattle, WA, USA) is using its proprietary multi-resolution 3Di platform for 3D spatial biology to develop artificial intelligence (AI) enabled smart microscopy. Alpenglow, in collaboration with CorePlus (Ponce, Puerto Rico), will utilize AI and 3D spatial biology to advance pathology from 2D qualitative to 3D quantitative. 3D imaging generates significantly more data than traditional slide-based methods by digitizing entire biopsy specimens instead of a single slice. AI and machine learning algorithms play a vital role in quantifying key biomarkers and identifying areas that require a more in-depth pathologist review. The aim is to automate the selection of tissue regions that require further scrutiny, which could eventually be instrumental in diagnosis or predicting responses to new therapies.
Alpenglow is advancing its smart microscopy platform, which employs its multi-resolution open-top light sheet microscope. Currently, the process for selecting areas of interest is manual and must be performed after data processing. Alpenglow plans to devise solutions for the quick processing of vast microscopy datasets, which can be a terabyte or larger in size, and locate areas of interest across extensive volumes using AI for higher sub-micron resolution imaging and additional quantitative analysis. As part of the collaboration, CorePlus will annotate 3D prostate biopsy images to train AI models to recognize critical tissue structures, including cancer cells, immune cells, and vessels.
In order to develop the next-generation AI-powered imaging technology, Alpenglow is integrating NVIDIA Holoscan, a leading platform for constructing medical devices that facilitate AI edge computing on 3Di. Additionally, Alpenglow will utilize NVIDIA IGX, a robust edge AI hardware platform, to function alongside 3Di. As a participant in the NVIDIA Inception program for innovative startups, Alpenglow is closely collaborating with the NVIDIA healthcare team to harness its GPU-accelerated image processing pipeline and expedite image processing on terabyte-scale datasets to enable automated region of interest detection. Alpenglow aims to speed up traditional pathology workflows, which can take from days to weeks, and deliver results in merely hours using the whole tissue sample.
“The future of pathology is 3D,” said Dr. Nicholas Reder, MD, MPH and CEO of Alpenglow Biosciences. “Alpenglow is poised to break the antiquated glass slide paradigm of pathology and usher in 3D spatial biology.”
Related Links:
Alpenglow Biosciences
CorePlus
Latest Pathology News
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Molecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Technology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
